A-share over 240 pharmaceutical companies' performance report: the revenue of innovative pharmaceutical companies soared by 94,408%

A-share pharmaceutical listed companies are gradually entering the peak period of performance reporting
.
Among the more than 240 pharmaceutical companies that have released annual reports, performance forecasts or express reports, there are three unprofitable pharmaceutical companies on the Science and Technology Innovation Board that have turned losses into profits
.
Relying on a number of authorized transaction revenue, Bio-Tech will achieve operating income of 829 million yuan in 2021, a year-on-year increase of 348.
04%; CanSino relies on the recombinant new coronavirus vaccine to achieve 4.
3 billion yuan in revenue, a year-on-year increase of 17174.
54%; the highest revenue growth rate The only one is Ellis, the only third-generation EGFR-TKI fumetinib was launched, allowing Ellis to gain a revenue increase of 94,407.
79%
.
Coincidentally, they all completed IPOs on the Science and Technology Innovation Board in 2020
.
In addition, Zhifei Bio, a leading domestic vaccine company, has become the only company in the A-share market with a net profit of over 10 billion yuan, reaching 10.
197 billion yuan
.
The IVD companies related to the monitoring of the new crown still showed a trend of soaring performance in the past year
.
01 Turning losses into profits, three companies are expected to take U.
According to Article 2 of the Shanghai Stock Exchange's "Notice on Matters Related to Transactions of Stocks and Depositary Receipts on the Science and Technology Innovation Board", the stocks of issuers that have not yet made a profit when listed on the Science and Technology Innovation Board should be marked accordingly.
: If the issuer has not yet made a profit, the special designation of its shares or depositary receipts is "U"; if the issuer realizes profit for the first time, the special designation will be cancelled
.
Since the opening of the STAR Market in July 2019, a total of 12 unprofitable biotech companies have gone public through the fifth set of standards on the STAR Market
.
Judging from the disclosed annual performance reports, express reports or forecasts, there are 3 companies that are expected to successfully turn losses into profits in 2021, namely Bio-Tech, CanSino and Ellis
.
Among the other 9 unprofitable listed pharmaceutical companies, 4 companies, BeiGene, Junshi Bio, Asieris, and Shanghai Yizhong, will reduce their losses in 2021; 5 companies to increase losses in 2021
.
Coincidentally, the three companies that will turn losses into profits in 2021 will all complete IPOs on the Science and Technology Innovation Board in 2020
.
Judging from the specific performance situation, Bio-Tech will achieve an operating income of 829 million yuan in 2021, a year-on-year increase of 348.
04%, a net profit of 85.
1785 million yuan, and a non-net profit of 39.
1653 million yuan
.
The reason for the sharp increase in Bio-Tech's performance is related to the substantial increase in its license-out revenue
.
In 2021, Bio-Tech conducted 3 licensing transactions in April, August and September, respectively
.
In April last year, Bio-Tech and Biogen reached an agreement on the tocilizumab biosimilar BAT1806
.
Bio-Tech will license the product's product rights outside of China to Biogen for up to $120 million in upfront and milestone payments, plus tiered royalties on double-digit percentages of net sales
.
In August, Bio-Tech and Hikma reached an agreement to license the exclusive product commercialization rights of ustekinumab injection BAT2206 in the U.
S.
market to Hikma for a fee, and received a total amount of up to 150 million US dollars for the down payment and milestone payments , and a double-digit percentage of net sales as the offer price
.
In September, Bio-Tech and Sandoz reached an agreement to license BAT1706's exclusive product commercialization rights in the United States, Europe, Canada and most other international markets not covered by BAT1706 cooperation to Sandoz for a fee
.
When the agreed conditions are met, Bio-Tech will receive up to $155 million in upfront and milestone payments, plus a double-digit percentage of profits
.
From this point of view, licensing revenue will account for an important part of Bio-Tech's revenue in 2021
.
In addition, Bio-Tech's adalimumab injection will also achieve growth in 2021.
It is expected that sales revenue will increase by 110 million yuan to 130 million yuan year-on-year, an increase of 60.
15%-71.
09% year-on-year
.
CanSino and Ellis relied more on product approvals to achieve significant performance growth
.
CanSino will achieve operating income of 4.
3 billion yuan in 2021, a year-on-year increase of 17174.
54%, net profit of 1.
914 billion yuan, and deducted non-net profit of 1.
797 billion yuan
.
The listing of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) (trade name: Keweisha) had a positive impact on the company's main business income and net profit attributable to owners of the parent company
.
Keweisha is the first adenovirus vector new crown vaccine approved for marketing in China, and the vaccine has also obtained emergency use authorizations from Mexico, Pakistan and other countries
.
Alice's operating income increased by 94,407.
79%, achieving an operating income of 530 million yuan and a net profit of 18.
2746 million yuan, but the deduction of non-net profit of -62.
0423 million yuan made Alice unable to win U this year
.
During the reporting period, the approval and listing of Vometinib was the main driving force behind the substantial increase in the revenue of Ailes' main business
.
At the same time, vormetinib, as the only third-generation EGFR-TKI, successfully entered the national medical insurance reimbursement catalog during the medical insurance negotiation in December last year
.
From this point of view, fumetinib will also be the main source of income for Ailes in the future
.
02The only A-share company with a net profit of over 10 billion yuan Among the A-share pharmaceutical companies that have disclosed their performance, Zhifei Biology came out on top with a net profit of 10.
197 billion yuan
.
Its 2021 annual performance report shows that during the reporting period, the company achieved operating income of 30.
637 billion yuan, a year-on-year increase of 101.
68%; net profit was 10.
197 billion yuan, a year-on-year increase of 208.
88%.
Zhifei Bio is also the only A-share listed pharmaceutical company that has disclosed performance.
A company with a net profit of over 10 billion yuan
.
Zhifei Bio is mainly engaged in the research and development, production and sales of vaccines and biological products
.
In the early days of establishment, the agency business was the main business.
After that, through independent research and development, it gradually established its own product system and formed a business model of "agent + independence".

.
Specifically, the independent products are mainly distributed in the three major sectors of bacterial vaccines, viral vaccines and tuberculosis prevention and control vaccines, mainly involving the prevention of meningitis, tuberculosis, pneumonia, influenza, rabies, norovirus infection and other human vaccine projects; agent Products include quadrivalent HPV vaccine, nine-valent HPV vaccine, pentavalent rota vaccine,
etc.
Among them, as the exclusive agent of Merck's quadrivalent and nine-valent HPV vaccines, the brokerage expects that the HPV vaccine business revenue will account for more than 80%
.
In addition, Zhifei Bio's recombinant novel coronavirus vaccine (CHO cells) is also boosting Zhifei Bio's performance
.
In the 2020 annual report, Zhifei Bio has disclosed that the company signed a cooperative research and development agreement with the Institute of Microbiology of the Chinese Academy of Sciences, and the recombinant novel coronavirus vaccine (CHO cells) jointly developed by the company started clinical trials in June 2020, and obtained I and II in October.
Key safety and immunogenicity data from a Phase 1 clinical trial
.
The new coronavirus vaccine was registered and marketed in Uzbekistan on March 1, 2021, becoming the first registered recombinant subunit new crown vaccine in the world; it was approved for emergency use in China on March 10 of the same year; on February 21 this year, the The vaccine is approved in China as a sequential (heterologous) booster vaccine for the new crown inactivated vaccine
.
Regarding the growth in performance, Zhifei Bio said that the company has increased investment in research and development to introduce new products, and the sales of independent products and agency products have continued to increase steadily.
The company's main business income, net profit and other important financial indicators have increased significantly compared with the same period of the previous year
.
03 How long will IVD last? The IVD sector is still showing a trend of concentrated and explosive performance
.
Enterprises related to in vitro diagnosis, including Rejing Bio, Jiu’an Medical, Yirui Bio, Jiuqiang Bio, Dongfang Bio, Wantai Bio, Nanowei Technology, Botuo Bio, Lanwei Medicine, and Mingde Bio, have performed very well and achieved outstanding performance.
The growth has more than doubled, and Rejing Bio has achieved an 18-fold increase in net profit
.
The performance report of Rejing Biology shows that the company achieved operating income of 5.
372 billion yuan, a year-on-year increase of 946.
14%; net profit attributable to owners of the parent company was 2.
193 billion yuan, a year-on-year increase of 1856.
81%
.
As for COVID-19 antigen testing companies, in addition to Hot View Bio, which has the largest performance increase, Jiu’an Medical and Oriental Bio have also achieved substantial growth
.
Judging from the performance forecasts of the two companies, during the reporting period, Jiu'an Medical's net profit was 900 million yuan to 1.
2 billion yuan, a year-on-year increase of 271.
40%-395.
19%, and the net profit of Oriental Bio was 4.
72 billion yuan to 5.
12 billion yuan, a year-on-year increase.
An increase of 181.
45%-205.
31%
.
In the past year, the demand for new crown antigen detection kits in overseas markets has increased significantly, which has achieved a substantial increase in the income of related companies
.
Taking Rejing Biology as an example, in the performance bulletin, Rejing Biology stated that the growth in performance was mainly due to the overseas sales of the novel coronavirus antigen detection kit it developed
.
In the first half of 2021, its novel coronavirus antigen detection kit was earlier certified by the German Federal Institute for Drugs and Medical Devices (BfArM) for home self-testing, and can be sold in supermarkets, pharmacies, Internet stores, etc.
Its foreign trade orders have exploded
.
In the second half of the year, it has successively obtained the self-test registration or filing of the EU CE and major economies such as the British MHRA and the French ANSM; especially in 2021Q4, affected by Delta and Omicron, Europe, Southeast Asia and other countries and regions have The demand for novel coronavirus antigen detection reagents continues to increase
.
Similarly, overseas demand for new coronavirus detection kits and other products from companies such as Jiu'an Medical and Oriental Bio is also very strong, and the increase in overseas sales performance has driven the growth of performance in 2021
.
At the same time as the performance surged, the market value of related companies also surged
.
For example, Jiu'an Medical, once known as the "demon stock"
.
The market value has risen from less than 4 billion yuan at the beginning of 2021 to more than 30 billion yuan, and the market value has increased by nearly 10 times
.
The new crown epidemic has indeed driven the development of the IVD industry
.
Since 2020, IVD companies have occupied the forefront of net profit growth in the A-share market
.
Judging from the performance forecast and express data of related companies this year, IVD companies involved in the new crown testing business are still "dominating the list"
.
After the epidemic, where will the performance of such companies go? The person in charge of the existing new crown testing business said that the company's performance at this stage depends on the progress of the global new crown epidemic prevention and control, the international epidemic's choice of technology products, as well as the company's product market competitiveness and channel capabilities, but whether future sales performance can continue.
To maintain a substantial growth trend, there are certain uncertainties
.
The "2020 China In Vitro Diagnostics Industry Report" shows that the rapidly developing new crown testing business will continue until 2024
.
For IVD companies, the post-epidemic era still needs to rely on more innovative products to achieve sustainable development of the company
.